Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Status
Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
960 (estimated)
Sponsor
PedAL BCU, LLC · Academic / Other
Sex
All
Age
22 Years
Healthy volunteers
Not accepted

Summary

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Detailed description

PRIMARY OBJECTIVES: I. To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available phase I/II Pediatric Acute Leukemia (PedAL) sub-trials. II. To maintain a longitudinal and comprehensive registry, as well as a specimen bank, from relapse in children and young adults with acute leukemias. OUTLINE: Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable). After completion of study, patients are followed up every 3 months for 2 years, and then every 6 months for 3 years.

Conditions

Interventions

TypeNameDescription
PROCEDUREBiospecimen CollectionUndergo collection of blood and/or bone marrow samples

Timeline

Start date
2022-04-18
Primary completion
2030-12-31
Completion
2030-12-31
First posted
2021-01-27
Last updated
2026-04-08

Locations

182 sites across 5 countries: United States, Australia, Canada, New Zealand, Puerto Rico

Source: ClinicalTrials.gov record NCT04726241. Inclusion in this directory is not an endorsement.